FDA approves Multibic, a mixed-electrolyte solution for continuous kidney therapy
Cleared 9 November for adults and children, the Fresenius two-compartment solution replaces fluid removed during continuous kidney replacement therapy and comes in three potassium strengths. It is an initial US approval.
The Food and Drug Administration has approved Multibic, a sterile replacement solution used during continuous kidney replacement therapy (CKRT), the slow, around-the-clock form of dialysis given to critically ill patients whose kidneys have failed [s1][s2]. The FDA approved the product on 9 November 2026 for Fresenius Medical Care Renal Therapies Group, under new drug application 219457; the label records it as an initial US approval [s1][s2].
CKRT is a fixture of the intensive care unit. When a patient in acute kidney failure cannot tolerate the rapid fluid shifts of standard intermittent haemodialysis, machines draw blood through a filter continuously, pulling off excess water and waste. Doing that removes a large volume of plasma water over a day, and that volume has to be given back in a controlled fluid whose electrolytes are set deliberately. Multibic is one of those fluids.
What it is approved for
The approved indication is specific. Multibic is indicated in adult and paediatric patients as a replacement solution in CKRT, to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances [s1][s2]. It is not a drug in the usual sense of a molecule with a pharmacological target; it is a precisely formulated salt-and-sugar solution, and its design is the point.
The solution is supplied as a 5,000 mL, single-dose, two-compartment bag whose contents must be mixed immediately before use, and the label specifies it be given only by an integrated pump within the extracorporeal blood-purification device — not infused like an ordinary IV bag [s1]. The label does not set a fixed dose: it directs that therapy be individualised to the patient's clinical condition and their fluid, electrolyte, acid-base, and glucose balance, the variables a CKRT circuit is run to control [s1]. The bag's two compartments, divided by a peel seam, hold the components apart until use: a 250 mL acidic electrolyte and dextrose solution in the small compartment and 4,750 mL of an alkaline bicarbonate solution in the large one, combined at the bedside into the ready-to-use fluid [s1].
The formulation
Multibic comes in three strengths that differ only in potassium — 2, 3, or 4 mmol/L — so a clinician can match the fluid to a patient's potassium needs [s1]. The rest of the recipe is held constant: after mixing, each litre delivers sodium at 140 mmol/L, bicarbonate at 35 mmol/L, calcium at 1.5 mmol/L, magnesium at 0.50 mmol/L, and dextrose at 5.55 mmol/L, which the label notes is 100 mg/dL [s1]. The bicarbonate is what buffers the blood's acid-base balance during treatment [s1].
That constancy is the clinical argument for a standardised, pre-formulated product: the variable a bedside team most often needs to adjust in CKRT is potassium, and holding everything else fixed narrows the room for a compounding or mixing error in a setting where those errors are dangerous.
The cautions
The label's warnings are the predictable hazards of pushing fluid and electrolytes through a sick patient for hours on end. It states that electrolyte and acid-base imbalances can occur and directs monitoring of potassium, sodium, calcium, magnesium, bicarbonate, phosphate, and pH [s1]. It also warns that treatment may affect glucose levels, that blood glucose should be monitored, and that antidiabetic therapy may need to be adjusted during treatment [s1]. These are monitoring instructions for the clinical team, not a home-use product.
What it adds
Multibic does not introduce a new mechanism or a new disease target; it adds a regulated, ready-to-mix option to the CKRT fluids US intensive care units can draw on, with a composition fixed by the label rather than assembled locally [s1]. For patients, the approval is invisible at the bedside — the fluid is one component of a therapy run entirely by the care team. Its significance is narrower and real: another approved, standardised solution for a therapy where the margin for a mixing error is thin.
This article describes a regulatory approval and is not medical advice.
Sources
- Multibic kidney replacement solution — Prescribing Information (NDA 219457, label revised 11/2026) — U.S. Food and Drug Administration (Drugs@FDA) , November 9, 2026
- NDA 219457 Approval Letter — Multibic kidney replacement solution (Fresenius Medical Care Renal Therapies Group, LLC) — U.S. Food and Drug Administration (Drugs@FDA) , November 9, 2026
Ventec recalls ventilators in Class I action over a connector that can reboot them
The FDA logged a Class I recall of Ventec's VOCSN, V+Pro, VC and V*Home ventilators on 28 October, citing an internal cable connector that can detach, rebooting the device and interrupting breathing support.
A phosphate binder for dialysis patients is cleared down to age six
On 13 October the FDA extended Velphoro (sucroferric oxyhydroxide) to children aged 6 to 9 on dialysis and added a 250 mg chewable tablet, widening an iron-based binder previously limited to patients 9 and older.
Abiomed recalls Impella heart-pump controllers in Class I action over sensor
The FDA logged the recall of 5,232 Automated Impella Controllers on 23 September, citing a possible purge-pressure sensor failure that can leave the console unable to recognise the pump's purge cassette.
FDA clears first generic of the Climara Pro menopause hormone patch
Announced 20 October, Zydus's once-weekly estradiol-and-levonorgestrel transdermal system is the first generic of Climara Pro, a combined oestrogen-progestogen patch for menopausal symptoms and bone loss.